Results of Operations and Financial Condition. On August 5, 2026, Vir Biotechnology, Inc. (the Company) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934,…

Chief Financial Officer — Jason O’Byrne: Jason O'Byrne is stepping down from his role as Chief Financial Officer to pursue another opportunity.

Class III director and Chair of the Audit Committee — Timothy Coughlin: The company expanded its board and appointed a new director with specific roles.

Director and Chair of the Audit Committee — Saira Ramasastry: Due to a business conflict, Saira Ramasastry is stepping down from her role as a member of the Board and Chair of the Audit Committee.

Results of Operations and Financial Condition. On May 6, 2026, Vir Biotechnology, Inc. (the Company) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, a…

Executive Vice President and Chief Medical Officer — Mark Eisner, MD, MPH: Dr. Mark Eisner is stepping down from his role as Executive Vice President and Chief Medical Officer.

President — Marianne De Backer, M.Sc., Ph.D., MBA: Dr. Marianne De Backer was appointed to the additional position of President.

Entry into a Material Definitive Agreement. On February 25, 2026, Vir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters named in Schedule I thereto (the Underwriters), in connection with the offer and sale by Vir Bio of 17,647,059 shares of common stock of Vir Bio, par value $0.0001 per share (Common…

Results of Operations and Financial Condition. On February 23, 2026, Vir Bio issued a press release announcing its financial results for the quarter and full year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.2 and is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.2, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amend…

Unregistered Sales of Equity Securities. The information under

Other Events. On February 23, 2026, Vir Bio issued a press release announcing updated results from the Phase 1 study of VIR-5500, which will be presented in an oral presentation at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium on February 26, 2026. A copy of the press release is filed herewith as Exhibit 99.3 and is incorporated herein by reference. Forward-Looking Statements This Current Report on Form 8-K (this Form 8-K) contains forward-looking statements w…

Entry into a Material Definitive Agreement. On February 19, 2026, Vir Biotechnology, Inc. (Vir Bio) and Astellas US LLC (together with its subsidiaries and affiliates (including its indirect parent, Astellas Pharma Inc.), Astellas) entered into a Collaboration and License Agreement (the Agreement). Upon closing of the transaction contemplated by the Agreement (the Closing and the Transaction, respectively), Vir Bio and Astellas will enter into a global strategic collaboration to co-develop an…

Results of Operations and Financial Condition. On January 12, 2026, Vir Biotechnology, Inc. (the Company) issued a press release that, among other things, provided its preliminary cash, cash equivalents and investments balance as of December 31, 2025, and delivered an update on its business. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. These preliminary cash, cash equivalents and investments balance result is unaudited and subject to…

Entry into a Material Definitive Agreement. On December 16, 2025, Vir Biotechnology, Inc. (Vir Bio) and Norgine Pharma UK Limited (together with its affiliates in the Norgine group of companies, Norgine) entered into a License Agreement (the Agreement) with respect to certain commercial rights to the combination of tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, for the treatment of people living with chronic hepatitis…

Other Events. Press Release On December 16, 2025 , Vir Bio issued a press release announcing the entry into the Agreement. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference. SOLSTICE Clinical Trial Update Certain data from the ongoing SOLSTICE Phase 2 clinical trial were presented in an oral session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® , in Washington, D.C., in November 2025 and simultaneous…

Results of Operations and Financial Condition. On November 5, 2025, Vir Biotechnology, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1…

Results of Operations and Financial Condition. On August 6, 2025, Vir Biotechnology, Inc. (the Company) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as…

Results of Operations and Financial Condition. On May 7, 2025, Vir Biotechnology, Inc. (the Company) issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as a…

Results of Operations and Financial Condition. On February 26, 2025, Vir Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securitie…

Chief Technology Officer — Ann (Aine) M. Hanly: The departure of the CTO is an orderly succession with a named internal successor assuming the responsibilities, indicating a planned transition rather than a sudden loss.

Results of Operations and Financial Condition. On October 31, 2024, Vir Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange…

CFO — Jason O'Byrne: The filing announces the appointment of an external candidate as Executive Vice President and Chief Financial Officer, which is a significant management addition rather than a departure.

Completion of Acquisition or Disposition of Assets. On September 9, 2024, Vir Biotechnology, Inc. (the “Company” or “Vir”) and Amunix Pharmaceuticals, Inc., a Sanofi company (“Sanofi”) closed the transaction contemplated by the previously-announced License Agreement entered into between the parties on July 31, 2024 (the “Transaction” and the “Agreement”, respectively). Upon closing of the Transaction (the “Closing”), the Company obtained an exclusive (even as to Sanofi and its affiliates), wo…

Entry into a Material Definitive Agreement. On July 31, 2024, Vir Biotechnology, Inc. (the “Company” or “Vir”) and Amunix Pharmaceuticals, Inc., a Sanofi company (“Sanofi”) entered into a License Agreement (the “Agreement”). Upon closing of the transaction contemplated by the Agreement (the “Closing” and the “Transaction”, respectively), the Company will obtain an exclusive (even as to Sanofi and its affiliates), worldwide, royalty-bearing, sublicensable (through multiple tiers in accordance…

Costs Associated with Exit or Disposal Activities. On July 29, 2024, the Company, by its duly authorized officer, approved a strategic restructuring plan to advance the development of its clinical portfolio and focus on the highest-value near-term opportunities. The strategic restructuring plan is designed to optimize the Company’s cost structure by reducing the size of its workforce in alignment with the Company’s current goals and strategy. The Company is prioritizing investment in the clin…